STOCKS TELEGRAPH

Tag: DRMA

  • Dermata Therapeutics (DRMA) Stock Faces Challenges Ahead

    Dermata Therapeutics Inc. (NASDAQ: DRMA) is a biotechnology company, which, as its name suggests, operates in the realm of dermatology. It aims to make a breakthrough in acne treatment, with its DMT310 candidate, yet recent updates demonstrate that severe challenges still lie ahead for DRMA stock.

    Dermata Shares Underwhelming Updates

    Earlier this month, Dermata Therapeutics Inc. (DRMA) reported on progress relating to its inflammatory skin disease candidate, DMT310. The management revealed that none of the primary endpoints could be attained within the study, despite no sign of any serious adverse conditions arising. The company has stated that despite the setback, it remains fully committed to proceeding with DMT310, and has even requested the FDA for a phase-2 end meeting. Management remains confident that the drug would establish itself as a viable acne treatment before March 2023.

    Financial Pressure Pushes on for DRMA

    In addition to facing disappointing trial update results for DMT310, Dermata is also faced with gradually mounting financial pressure, which cannot subside in the wake of poor results. The company’s cash holdings are down from $10.8 million to $8.1 million in less than a year. Although Dermata management states it has sufficient runway to fund operations until FY23Q3, the time is ticking for shareholders. Similarly, its R&D costs have doubled year-over-year from $800,000 to over $1.6 million. General and administrative expenses however remained constant over the year at $900,000. Additional funding could face challenges as a result of tight capital markets, and uncertainty regarding the prospects and viability of DMT310.

    Conclusion

    DRMA, like any biotech company, is one that is wrought with significant uncertainty. However, its immediate prospects appear challenging, given its failure to deliver, in terms of its DMT310 candidate. If the company successfully turns this around, it can tap into a multi-billion dollar global market, with relative ease.

  • Dermata Therapeutics, Inc. (DRMA) stock gained in the Pre-market; here is why?

    Dermata Therapeutics, Inc. (DRMA) stock gained in the Pre-market; here is why?

    Dermata Therapeutics, Inc. (DRMA) gained in the pre-market after submitting two-sec filings. DRMA values at $1.40, gaining more than 30% compared to yesterday’s closing price. The stock closed at $1.07 at the end of the last trading session. The stock volume traded in the last trading session was around 224.22K shares. The current market cap of the company is around $8.91 million.

    The SEC Filings

    Dermata Therapeutics, Inc. has asked the FDA to waive the 90-day dermal minipig study and standard dermal pharmacokinetic study requirements for its DMT310 acne program. DMT310 has been well-tolerated in over 170 human patients. It is a 180-person Phase 2 rosacea trial. After the 90-day dermal minipig study, human trials are usually required. The company could cite the FDA’s Botanical Drug Development Guidance for Industry, and the FDA approved DMT310 for human trials without the 90-day dermal minipig study. Waiver of 90-day dermal minipig study based on DMT310 human safety data and historical data hopes to save $600,000 if the FDA approves the 90-day dermal minipig waiver. That is why an NDA is required.

    FDA also waived the dermal pharmacokinetic study. The company seeks DMT310 tolerance and safety waiver. It will start in late 2022 if the FDA grants both waiver requests. In 2022, the company could complete the standard dermal pharmacokinetics study and start the Phase 3 program. Phase 3 could delay until 2023 due to the 90-day dermal minipig study’s supply chain issues.

    In another sec filing, the company announced its general statement of registration for all businesses, including those issuing face-amount certificates.

    DRMA was down yesterday, but today, it is skyrocketing

    They lost more than 20% at the end of the last trading session after announcing the sec filings. However, today, in the pre-market, it is skyrocketing and gained value of more than 30%. The company went public last year, and since then, it has been on the decline and losing its value.

    Conclusion

    Dermata Therapeutics, Inc. (DRMA) is looking forward to a significant breakthrough in the research that could become a revenue stream. The company is at the pre-revenue stage right now and is losing money.

  • Dermata Therapeutics, Inc. (DRMA) Stock Plunged in Aftermarket, Here’s What Happened?

    Dermata Therapeutics, Inc. (DRMA) Stock Plunged in Aftermarket, Here’s What Happened?

    Dermata Therapeutics, Inc.  (DRMA) is a biopharmaceutical company engaged in bringing the therapeutic potential for different dermatological conditions. One of the lead candidates of the company is DMT310, which is under the clinical development stage for treating acne, psoriasis, and rosacea. It is derived from the freshwater sponge and utilizes the company’s Spongilla technology portfolio. Another candidate is DMT410 is used for treating numerous aesthetic and medical skin conditions.

    The price of DRMA stock during the regular trading on February 4, 2022, was $2.22 with a 0.91% incline. At last check in the aftermarket, the stock dropped by 18.92%.

    DRMA: Events and Happenings

    On February 4, 2022, DRMA reported about multiple SEC filings including Securities Act Rules of free writing prospectuses, current report, and general form of the registration statement for face-amount certificate companies. On January 13, 2022, DRMA reported about appointing Brittany Bradrick to the Audit Committee and Board of Directors of the company. She had already served as CFO of Neurelis, Inc., and ViaCyte.

    On January 5, 2022, DRMA announced that its senior leadership participated at the Virtual H.C. Wainwright BioConnect Conference on January 10-13, 2022. On November 19, 2021, DRMA announced hopeful safety and efficacy data from Phase 1 clinical trials of DMT410. The results were presented at the 2021Annual Meeting of the American Society for Dermatologic Surgery. On November 17, 2021, DRMA reported about the enrollment of the preliminary patients in Phase 2 clinical trials of DMT310.

    DRMA: Key Financials

    On November 15, 2021, DRMA released its financial results for the third quarter ended September 30, 2021. Some of the key updates are below.

    EPS

    Basic and diluted net loss per share attributable to the company’s common stockholders in Q3 2021 was $4.2 million or $0.86 against $0.59 million or $0.31 in the same period of 2020. The company missed the estimated EPS by $0.61.

    Assets

    Total assets of the company recorded in Q3 2021 were $13.6 million.

    Conclusion

    DRMA stock is 57% down the past six months but it outperformed in the last one month period by 41%. The company’s stock dipped again in Friday’s aftermarket session as the result of multiple SEC filings reported by the company. There is no other recent press release or event on the company’s calendar. The analysts are estimating the company’s EPS for the upcoming quarter to be -$0.39.

  • Dermata Therapeutics Inc. (DRMA) stock Continues Rising After Hours. Why?

    On January 24, Dermata Therapeutics Inc. (DRMA) stock advanced by a further 8.67% in the after-hours. Before that, the stock had already added 5.49% during the regular trading session.

    DRMA stock closed the regular session at $1.73, after fluctuating between $1.43 and $1.73. The stock went on to add a further $0.15 in the after-hours to reach $1.88 on Monday.

    Dermata Therapeutics Inc. which is a clinical-stage medical dermatology company has a market capitalization of $13.66 million. Currently, the company has 8.33 million shares outstanding in the market.

    DRMA stock Movement

    On January 13, the company announced the addition of a new director to its board. Following the announcement, the stock started gaining on January 14 and hence entered an uptrend. DRMA continued the uptrend till January 21, when it suffered some loss. The stock has since been once again on a bullish path.

    Although there is no new official announcement, SEC filing, or any upcoming event, DRMA has added 11.61% in the past five days. Moreover, the stock suffered a loss of 6.99% last month and 61.73% in the past three months.

    Recent Developments

    Recently, on January 13, DRMA announced the appointment of Brittany Bradrick to its Board as well as the Audit Committee. Ms. Bradrick has vast experience of over 25 years in finance, strategy, and corporate development for life science companies. Furthermore, she has served with Neurelis, ViaCyte, Insulet Corporation, Abbott Diabetes Care, and many others. Ms. Bradrick has served at various positions with these companies including CFO, COO, VC Strategy & Corporate Development, Head of Global Development, and others. Prior to this, she also served as the investment banker for the life science industry.

    Before that, the company participated in the H.C. Wainwright BioConnect Virtual Conference which took place on January 10-13, 2022. DRMA’s Chairman of the board, president and CEO, Gerry Proehl, presented an overview of the company at the conference.

    DRMA’s Financial Analysis

    On November 15, the company declared its financial results for the third quarter of 2021, which ended on September 30.

    In the third quarter of 2021, the company had research and development expenses of $0.8 million. Comparatively, R&D expenses were $0.1 million in the year-ago quarter.

    Additionally, the general and administrative expenses in Q3 2021 were $0.9 million against $0.4 million in Q3 of 2020.

    DRMA ended the third quarter with cash of $12.6 million on September 30, 2021.